A bill to clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers; to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

H.R. 2315 — A bill to clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers; to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Cosponsors added, H2001 [26FE], H2065 [27FE], H2258 [6MR], H2302 [11MR], H2566 [21MR], H2611 [24MR], H2645 [25MR], H2854 [2AP], H3199 [10AP], H3409 [1MY], H4017 [8MY], H4685 [20MY], H4910 [28MY], H5024 [29MY], H5877 [8JY], H6107 [10JY], H7297 [8SE], H7893 [18SE]

Cosponsors added (submitted January 21, 2014), H1252 [23JA]